Trial Profile
A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA [hydrofluoroalkane] (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 Inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Oct 2006 to Feb 2007 as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2007 Status changed from recruiting to in progress.